Tech Company Financing Transactions
Asher Bio Funding Round
Asher Bio closed a $108 million Series B venture capital round on 9/2/2021. Investors included Wellington Management Company, Alexandria Venture Investments and Boxer Capital.
Transaction Overview
Company Name
Announced On
9/2/2021
Transaction Type
Venture Equity
Amount
$108,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to lead cis-targeted immunotherapy, AB248, through clinical proof-of-concept, while advancing a second program through investigational new drug (IND)-enabling studies and continuing to invest in its cis-targeting platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
650 Gateway Blvd. 100
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Craig Gibbs
Chief Operating Officer
Kyle Elrod
Chief Scientific Officer
Ivana Djuretic
Chief Technical Officer
Andrew Yeung
VP - Bus. Development
Sheldon Okada
VP - Regulatory Affairs
James Cross
Browse more venture capital transactions:
Prev: 9/2/2021: Checkr venture capital transaction
Next: 9/2/2021: Disc Medicine venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs